REFERENCES
- Brennan MJ. Genomic medicine. Pract Pain Manage. 2012;12(7):1–3.
- Vuilleumier PH, Stamer UM, Landau R. Pharmacogenomic considerations in opioid analgesia. Pharmgenomics Pers Med. 2012;5:73–87. doi: 10.2147/PGPM.S23422.
- Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J Pain. 2010;26(1 Suppl):S16–S20.
- American Medical Association. Pharmacogenomics: Increasing the safety and effectiveness of drug therapy. 2011. Available at: http://www.ama-assn.org/resources/doc/genetics/pgx-brochure-2011/pdf. Accessed June 1, 2012.
- Branford R, Droney J, Ross JR. Opioid genetics: the key to personalized pain control? Clin Genet. 2012;82:301–310. doi: 10.1111/j.1399-0004.2012.01923.x.
- Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;92:467–475. doi: 10.1038/clpt.2012.120.
- Mayo Reference Services. Communique. September 2005. Available at: http://www.mayomedicallaboratories.com/media/ articles/communique/mc2831-0905/pdf. Accessed June 1, 2012.
- Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007;37:301–314.
- Ablin JN, Buskila D. Personalized treatment of pain. Curr Rheumatol Rep. 2013;15:298–303. doi: 10.1007/s11926-012- 0298-7.
- Kirsh KL, Fishman SM. Multimodal approaches to optimize outcomes of chronic opioid therapy in the management of chronic pain. Pain Med. 2011;12(Suppl 1):S1–S11. doi: 10. 1111/j.1526-4637.2010.00992.x.
- Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther. 2000;17:70–83.
- Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indianapolis: Indiana University School of Medicine; 2007. Available at: http://medicine.iupui.edu/ clinpharm/ddis/table.aspx. Last accessed October 13, 2013.
- Koka S, Beebe TJ, Merry SP, The preferences of adult outpatients in medical or dental care settings for giving saliva, urine or blood for clinical testing. J Am Dent Assoc. 2008;139:735–740.
- Selkirk CG, Weissman SM, Anderson A, Hulick PJ. Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet Test Mol Biomarkers. 2013;17:219–225. doi: 10.1089/gtmb.2012.0165.
- Tennant F. Cytochrome P450 testing in high dose opioid patients. Pract Pain Manage. 2012;(August):43–58.
- Jannetto PJ, Bratanow NC. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics. 2009;10:1157–1167.
- Smith H. Opioid metabolism. Mayo Clin Proc. 2009;84: 613–624.
- Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48:689–723.
- Sutton VR. Tay-Sachs disease screening and counseling families at risk for metabolic disease. Obstet Gynecol Clin North Am. 2002;29:287–296.
- Weissman DE. Understanding pseudo-addiction. J Pain Symptom Manage. 1994;9:74–75.
- Weissman DE. Pseudo-addiction #69. J Palliat Med. 2005;8:1283–1284.
- Weissman DE, Haddox JD. Opioid pseudo-addiction—an iatrogenic syndrome. Pain. 1989;36:363–366.
- Passik SD, Webster L, Kirsh KL. Pseudoaddiction revisited: a commentary on clinical and historical considerations. Pain Manage. 2011;1:239–248.
- Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26:601–608.
- Wu AC, Fuhlbrigge AL. Economic evaluation of pharmacogenetic tests. Clin Pharmacol Ther. 2008;84:272–274.
- Winner J, Allen JD, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenetics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 2013;3:1–6.
- Herbild L, Andersen SE, Werge T, Rasmussen HB, Jurgens G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharmacol Toxicol. 2013;3:1–7.
- Payne K, Shabaruddin FH. Cost-effectiveness analysis in pharmacogenomics. Pharmacogenomics. 2010;11:643–646.
- Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics. Pharmacoeconomics. 2010;28: 1001–1013.